Agenda

Friday, June 3

7:30 a.m. Registration / Breakfast

8:30 a.m. Welcome / Introduction to ARS

8:45 a.m. ACC.16 Late Breaking Clinical Trials: How Will They Impact Your Practice?

9:30 a.m. Session I: Arrhythmias
   Drs. Indik and Patton

   Learning Objectives:
   Upon completion of this session, participants should be able to --
   • Appropriately integrate the emerging evidence and options for prevention, detection, risk assessment, rhythm and rate management, and stroke prevention into the care of patient with atrial fibrillation (AF)
   • Integrate findings from family history, ECG, molecular, and genetic testing to assess and mitigate risk of sudden cardiac death
   • Appropriately manage patients with a cardiac implantable device
   • Prevention of AF – latest update on obesity, lifestyle changes, sleep disorders, pollution
   • Prevention of AF-related stroke
   o Novel tools for risk stratification (smartphone applications, implantable loop recorders)
   o Using DOACs safely
   o Left atrial appendage occlusion/Watchman
   • What’s new in AF epidemiology/management
   o AF in older populations, men vs. women, cognitive dysfunction, exercise
   o Ablation candidate selection
   • Practical CIED Management
   o Who Should Receive a Subcutaneous ICD?
   o Can my patient with a device have an MRI?
   o The skin looks red over the device, what do I do?
   • Sudden Cardiac Death
   o Making the diagnosis – Why did this happen and who in the family is at risk?
   o Athletes and Screening – Who can play?
   o Evaluation of syncope – Who is at risk for sudden death?

11:00 a.m. Break

11:15 a.m. Session II: Acute Coronary Syndromes
   Drs. de Lemos and Hirsch

   Learning Objectives:
   Upon completion of this session, participants should be able to --
   • Tailor the timing, selection, dosing, combination and duration of adjunctive and long-term antithrombotic therapy regimens for individual patients with acute coronary syndromes (ACS)
   • Scrutinize the methodology of recent ACS clinical trials to determine the implications and generalizability of findings
   • Evaluate the evidence and different perspectives underlying current controversies in ACS management
   • Detect and manage non-obstructive pathology and coronary anomalies that may present as ACS or complicate management
Bringing Science to Clinical Practice: Best of ACC

Themes to be discussed in this session include:
- Myocardial infarction with normal coronary arteries (MINOCA): a common conundrum? ... or “you can’t say you haven’t heard of it anymore”?
- Optimizing antiplatelet and anticoagulant therapy
  - Dual antiplatelet therapy: how long and how strong?
  - Triple therapy (and double trouble?)
- Late breaking trial updates from the ACC
  - New treatment targets in inflammation and cardiac protection
  - Going retro: revisiting IV beta blockers in the modern era
  - When electricity isn’t enough: Antiarrhythmic drugs for out of hospital arrest

12:40 p.m. Lunch Session: Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

1:40 p.m. Break

2:00 p.m. Session III: Heart Failure
Drs. Dec and Desai

Learning Objectives:
Upon completion of this session, participants should be able to:
- Analyze the evidence on new and established pharmacotherapies for heart failure management
- Integrate contemporary concepts on pathogenesis into the evaluation and management of patients with heart failure and cardiomyopathy
- Utilize findings from noninvasive imaging to clarify the etiology and guide the management of patients with heart failure or cardiomyopathy

Themes to be discussed in this session include:
- Hot New Drugs for Heart Failure
- Cardiomyopathies -- Focus on Amyloid and Cancer-related injury
- Imaging in Heart Failure

3:30 p.m. Break

3:45 p.m. Building Consensus at the Table: Case Challenges

5:00 p.m. Adjourn

Saturday, June 4

7:30 a.m. Breakfast

8:00 a.m. Session IV: Valvular Heart Disease
Drs. Bonow and Kodali

Learning Objectives:
Upon completion of this session, participants should be able to:
- Evaluate the evidence and controversies associated with recent changes to the classification framework and treatment thresholds outlined in valvular heart disease (VHD) Guidelines
- Integrate understanding of etiology, mechanisms, natural history, and risk markers into the care of patients with right and left-sided valve disease
- Incorporate the evidence on contemporary surgical, percutaneous, and device-based treatment options into clinical decision-making for patients with VHD

Themes to be discussed in this session include:
- Growing Pains of Valve Disease
  - TAVR Update
  - Partner 2 Intermediate Risk trial
- Expanding indications and role in lower risk populations
In-Hospital TAVR Risk Calculator (ACC App released Dec 2015)
Contemporary role and advances in surgical AVR
When should we not treat? (futility)
• Aortic Stenosis – Key Issues in Assessing and Management
• Mitral Regurgitation
  • Expanding transcatheter and device options
  • No data yet for FMR
• 2015 Guideline/ECD Update
  • Bethesda/Athlete with VHD
  • Clarification Statement – Aortic Root Intervention in BAV
  • Endocarditis (2015 AHA Scientific Statement)
• Quality Gap in Echo for VHD
• Procedural Volume, Operator and Institutional Requirements for Advanced Valve Care, Centers of Excellence

9:30 a.m.  Break

9:45 a.m.  Session V: Prevention
Drs. Kates and Smith

Themes to be discussed in this session include:
• Global Understanding of Current Burden of CVD
• Hypertension – New and Old
• Cholesterol Guidelines

Learning Objectives:
Upon completion of this session, participants should be able to --
• Describe the role of genetics in lipid metabolism, cardiovascular CVD risk, and response to pharmacotherapy and the clinical implications for CVD risk assessment and lipid management
• Apply current evidence base to determine thresholds for hypertension treatment, establish therapeutic goals, and implement system-based processes to achieve timely blood pressure control
• Evaluate often conflicting recommendations as well as the underlying evidence on lipid

11:15 a.m.  Building Consensus at the Table: Case Challenges

12:00 p.m.  Course Adjournment